Treating pain in patients with hepatic impairment
DC CAFCFirst Claim
1. A method of treating pain in a patient having mild or moderate hepatic impairment, the method comprising:
- administering to the patient having mild or moderate hepatic impairment an oral dosage unit having hydrocodone bitartrate as the only active ingredient, wherein the dosage unit comprises an extended release formulation of hydrocodone bitartrate, wherein the dose is not adjusted for the patient having mild or moderate hepatic impairment and wherein the dosage unit provides a plasma half-life of hydrocodone of about 8 hours in patients without hepatic impairment.
3 Assignments
Litigations
0 Petitions
Accused Products
Abstract
An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment.
18 Citations
20 Claims
-
1. A method of treating pain in a patient having mild or moderate hepatic impairment, the method comprising:
administering to the patient having mild or moderate hepatic impairment an oral dosage unit having hydrocodone bitartrate as the only active ingredient, wherein the dosage unit comprises an extended release formulation of hydrocodone bitartrate, wherein the dose is not adjusted for the patient having mild or moderate hepatic impairment and wherein the dosage unit provides a plasma half-life of hydrocodone of about 8 hours in patients without hepatic impairment. - View Dependent Claims (2, 3, 4)
-
5. A method of treating pain in a patient having mild hepatic impairment, the method comprising:
administering to the patient having mild hepatic impairment an oral dosage unit having about 20 mg of hydrocodone bitartrate as the only active ingredient, wherein the dosage unit comprises an extended release formulation of hydrocodone bitartrate.
-
6. A method of treating pain in a patient having moderate hepatic impairment, the method comprising:
administering to the patient having moderate hepatic impairment an oral dosage unit having about 20 mg of hydrocodone bitartrate as the only active ingredient, wherein the dosage unit comprises an extended release formulation of hydrocodone bitartrate.
-
7. A method of treating pain in a patient having mild or moderate hepatic impairment, the method comprising:
administering to the patient having mild or moderate hepatic impairment an oral dosage unit having hydrocodone bitartrate as the only active ingredient, wherein the dosage unit comprises a first formulation of hydrocodone bitartrate and a second formulation of hydrocodone bitartrate, and wherein the dose is not adjusted relative to a patient without hepatic impairment. - View Dependent Claims (8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
Specification